Search - tctmd.com

Displaying 781 - 799 of 799

Sort: Relevancy | Date

News Daily News

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

Jason Kahn

October 11, 2013

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

News Daily News

JAMA Review Tackles Intricacies of Medical Therapy After PCI

Caitlin E. Cox

July 11, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

News Daily News

Meta-analysis Questions Benefit of Longer Dual Antiplatelet Therapy Post-PCI

November 28, 2012

News Daily News

Meta-análisis cuestiona beneficio de la terapia antiplaquetaria doble extendida después la PCI

November 28, 2012

News Daily News

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

L.A. McKeown

August 09, 2012

News Daily News

Pantoprazole Not Necessarily a Safer PPI Choice for Patients on Dual Antiplatelet Therapy

L.A. McKeown

August 01, 2012

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

News Daily News

Meta-Analysis: Adjunctive Cilostazol Lowers Repeat Revascularization After PCI

Caitlin E. Cox

March 07, 2012

News Daily News

Meta-Análisis: Cilostazol Adyuvante Reduce la Necesidad de Volver a Revascularizar tras una PCI

Caitlin E. Cox

March 07, 2012

News Daily News

Six Months Sufficient for Dual Antiplatelet Therapy

Jason Kahn

October 17, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

News Conference News

EXCELLENT Outcomes Regardless of Antiplatelet Therapy Duration After DES

Caitlin E. Cox

April 05, 2011

News Daily News

Cilostazol Reduces Repeat Revascularizations for Long Lesions

March 06, 2011

News Daily News

CILON-T Published: Cilostazol Reduces Platelet Reactivity, Not Events

January 09, 2011

News Daily News

Dabigatran an Alternative to Warfarin for Stroke Prevention in A-Fib Patients

Kim Dalton

September 03, 2009

News Daily News

JUPITER: Rosuvastatin Cuts Heart Risk, Even In LDL-Normal Patients

November 11, 2008

CME

Advertisement

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

JAMA Review Tackles Intricacies of Medical Therapy After PCI

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Meta-analysis Questions Benefit of Longer Dual Antiplatelet Therapy Post-PCI

Meta-análisis cuestiona beneficio de la terapia antiplaquetaria doble extendida después la PCI

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

Pantoprazole Not Necessarily a Safer PPI Choice for Patients on Dual Antiplatelet Therapy

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

Meta-Analysis: Adjunctive Cilostazol Lowers Repeat Revascularization After PCI

Meta-Análisis: Cilostazol Adyuvante Reduce la Necesidad de Volver a Revascularizar tras una PCI

Six Months Sufficient for Dual Antiplatelet Therapy

Long-term Antiplatelet Therapy: All Risk, No Benefit

EXCELLENT Outcomes Regardless of Antiplatelet Therapy Duration After DES

Cilostazol Reduces Repeat Revascularizations for Long Lesions

CILON-T Published: Cilostazol Reduces Platelet Reactivity, Not Events

Dabigatran an Alternative to Warfarin for Stroke Prevention in A-Fib Patients

JUPITER: Rosuvastatin Cuts Heart Risk, Even In LDL-Normal Patients

Optimizing the Duration of DAPT following PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content